This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Antares Pharma, Inc.
5/6/2021
Ladies and gentlemen, welcome to the Ontario's Pharma First Quarter 2021 Financial and Operator Results Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference over to Tram Bui, Ontario's Vice President of Corporate Communications and Investor Relations. Please go ahead.
Thank you, Operator, and good morning, everyone. Earlier today, we announced our first quarter 2021 financial results and operating achievements. A copy of the press release and slide presentation for today's conference call are available in the investor relations section of the Antares Pharma corporate website. Before we begin, I'd like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include those related to our future financial and operating results, including our expectations regarding the impact of the ongoing COVID-19 pandemic and mitigation measures implemented in response to the outbreak on our overall business, operating results, and financial condition, our ability to achieve the 2021 revenue guidance, future revenue growth, prescription volumes, and market share for our products and our partner products, including Zyastad, Atrexib, Nocturna, and Tevis Generic EpiPen, FDA actions and other regulatory activities, including actions with respect to McKenna and approval of Tevis Pending Andes for generic Forteo and Bayeta, timing and results of ongoing and future development programs and clinical trials, including ATRS 1901 and 1902, as well as programs with Pfizer and Adorsia and other product development activities and business development efforts. These forward-looking statements are subject to certain risk and uncertainties, and actual results could differ materially. They are identified and described in today's press release, in the accompanying slide presentation on slide two, and in the company's filings with the SEC on Form 10-K, and as updated in Ontaris' recent periodic filings on Form 10-Q and Form 8-K. Ontaris is providing this information as of the date of today's conference call, and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events, or circumstances after the date hereof, except as required by law or otherwise. The company cautions investors not to replace undue reliance on these forward-looking statements. Joining me on the call today are Bob Apple, President and Chief Executive Officer, and Fred Powell, Executive Vice President and Chief Financial Officer. Let's review the agenda for today's call on slide three. Bob will begin with a review of our overall business, including our commercial achievements and strategy for our proprietary portfolio, as well as provide an update on our partner business. Fred will then go through the detailed financials, and Bob will conclude with closing comments before opening up the line for your questions. Please turn to slide four, and I will hand the call over to Bob Apple.
Bob? Thanks, Charm, and good morning, everyone. Thank you for your interest in our first quarter results and operations update. We are pleased to have started the year with strong financial results, with record first quarter revenue increasing 27% to $42 million, with a reported net income of $3.8 million, or two cents per share. In the first quarter, we continued to increase the adoption of Zycet that drove the 48% revenue increase in our proprietary products to almost $19 million. As we look ahead, we expect increasing momentum throughout the year for Zyvested and Nocturna as our sales representatives enhance our targeting strategy and garner more in-office physician visits as the pandemic slows with increased vaccinations. These same vaccinations increases have also provided a temporary boost in demand for Teva's generic EpiPen, with total prescriptions increasing 48% year-over-year With a 53% share of the generic EpiPen market in the first quarter, their growth was the main driver of the almost 90% increase in our royalty revenue. As we continue to anticipate the U.S. approval and launch of Tevis Generic for Teo, alongside the growth opportunities of our commercial portfolio and partner business, we are reaffirming our full-year 2021 revenue guidance. Let's first focus on our proprietary portfolio on slide five. which collectively represents our highest margin business and remains a significant growth driver of the company. The strong demand for Zyvested drove the 60% increase in revenue for our flagship asset to more than $14 million in the first quarter compared to last year, despite seasonality that is typical across the industry. Q1 is always the most challenging quarter as the industry manages through the traditional dynamics of plan changes, payer coverage, and patient deductible resets. All the while, we continue to implement all across all of our access and affordability programs to help patients get their Zyacid prescriptions filled, particularly in this first quarter. Notwithstanding, according to IQVA data, total prescriptions for Zyacid increased 50% year-over-year, with March representing our highest month to date, and we expect continued growth throughout the year. We remain enthusiastic with the opportunity to compete in a growing testosterone market with Zyestead, particularly given the evolving industry dynamics due to the pandemic. As our sales reps continue to execute a hybrid detailing model of approximately 60% in person and 40% virtual detailing this quarter, we believe the advantages of Zyestead with an easy-to-use, once-weekly, virtually painless at-home testosterone replacement therapy will continue to garner brand recognition and adoption by physicians. We believe that the pandemic will continue to shift societal norms to seek at-home therapies, which are at the core of our platform technology and development portfolio. During the first quarter, our hybrid detailing model continued to prove effective, driving strong brand awareness and profile acceptance by our target audience, supporting a growing prescriber base and year-over-year prescription growth. We believe these accomplishments, when paired with an enhanced targeting strategy and new digital and social media promotional campaign that was recently introduced, have the brand poised for continued growth. And as the year progresses, we also expect our sales force to increase their productivity as they garner more in-office visits with a slowdown of the pandemic. We believe that the success that we have achieved thus far with Zyacid can be leveraged for the relaunch of Nocturna. Total prescriptions for Nocturna remain consistent with our expectations in year one of this relaunch. We believe this product is uniquely positioned to help patients suffering from nocturia due to nocturnal polyuria. Our learnings from the soft launch at the end of last year have translated into a new comprehensive marketing campaign, illustrated on slide six, that we believe will increase awareness, trial and adoption of Nocturna with our targeted physicians. We anticipate continuing to call on existing Zysted targets who have also the potential to prescribe Nocturna to assure we allocate the appropriate selling time to reestablish Nocturnal while also remaining focused on Zysted. Furthermore, we also have a select group of new high-potential Nocturna targets who our sales force will be able to reach with minimal distraction to Zysted. With that overview of our commercial portfolio, I'd like to take this opportunity to welcome Joe Randa to the company as our new Senior Vice President of Commercial. Joe brings considerable commercial experience from large and mid-sized pharma companies, where he has led commercial organizations with significant revenue. He has also proved successful across therapeutic areas, and we look forward to his contributions to our sales, marketing, and data analytics that we believe will enhance our strong growth trajectory. His broad therapeutic experience also aligns with our initiatives to continue to expand our commercial portfolio through business development. On that same note, we are also very pleased to have Dr. Peter Richardson join our leadership team as Executive Vice President, Research and Development, and Chief Medical Officer. Peter joins us at a very exciting juncture of our internal development with a proven track record of success in managing development programs and clinical trials that have resulted in multiple product approvals. We look forward to being able to leverage his extensive research and development background as we advance ATRS 1901 and 1902
You're reading a preview of the ATRS Q1 2021 earnings call.
Free account.